OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection - Wikidata - awgldk - TriplyDB

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

http://www.wikidata.org/entity/Q24655506

about

Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon.Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance Microbiome mediation of infections in the cancer setting Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition.Antibiotics and bacterial resistance in the 21st century.Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.Clostridium difficile and the microbiota Treatment of Clostridium difficile infection: recent trial results.Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections Future novel therapeutic agents for Clostridium difficile infection.Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.Differences of the Fecal Microflora With Clostridium difficile Therapies.In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.Fidaxomicin--the new drug for Clostridium difficile infection Breakthroughs in the treatment and prevention of Clostridium difficile infection.Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin The Antimicrobial Stewardship Approach to Combating Clostridium Difficile.The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge The membrane as a target for controlling hypervirulent Clostridium difficile infections.Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota.Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid Diagnostics Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile.Clostridium difficile infection in the intensive care unit.In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.Variations in virulence and molecular biology among emerging strains of Clostridium difficile.Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.

P2860

Q24632558-58862FFA-A097-459F-9DDC-62AC315006F7 Q24632641-E79E4945-7774-488C-996D-1672238C8E76 Q26752672-5730E74F-F682-4460-9BEE-03FD15AA3309 Q30277636-131E2B3B-558D-4096-BC3F-5D4ADFC909A1 Q30417830-C922E386-7124-48A4-B6C4-39D8A1046394 Q30425705-3921F906-4AC9-40B3-ACDE-B92BA429CDED Q33777945-4460B177-A2B7-4AE6-B026-F180FC27841B Q34156349-EC28A6BD-9E94-4A4C-83C4-7101A65E455B Q34306091-DFB3CADE-AD17-4344-9DD6-AA59C7F8A06C Q34311594-5E9D2D96-962B-41E3-8AF3-9F7EC27BFE7E Q34710368-82F7A03C-EB6F-4CC7-816B-9CC79B9AAFC9 Q35009326-2A40C77E-3FE5-4784-9BFF-B140B5378C3F Q35146382-2E420E73-C31D-4EEA-BAC8-8ED9392EEE4F Q35164536-F7AC484D-B604-4DEF-BB1D-7B978EF7A95E Q35175136-56BBA97D-A4A7-4FF4-A547-EC957AB7C99A Q35191412-7FBE48F4-2705-4C9E-AE25-B619606E98F3 Q35199072-AFCCEC52-9A9F-4BFA-9D50-4BBEDCA155DE Q35617263-CC175C7A-57BE-4E3C-8E69-19F55884F8DB Q35806432-6895E70B-0C8D-4C33-B6A2-B3A7B7EDFDD6 Q35877773-363EA61C-040B-4297-91CF-0EA67FAC7CF8 Q35918566-2A9455E8-A7FF-4423-893F-3EEA28D903D6 Q35941496-CC089855-036C-4617-AC06-5122EBBF7CB2 Q36071501-F05A6ECC-E5C2-41DF-92C3-908F54682870 Q36071504-6CC678C4-9B09-430D-8F3E-3F58752C6856 Q36071520-6DD0F182-2B28-4D80-9FBB-37F5DF12D18D Q36071524-DEBC9E17-9772-4056-8527-D8464B7E9F86 Q36683557-6DC1B174-C7A6-4F93-B2E3-2DDA5FA0C1C6 Q36889259-55FE2ED7-FCFD-439F-B16C-BD5014760266 Q36963920-08D61758-CABD-4A65-8EF4-EA12A84D4344 Q37023237-A217E6BF-9E65-45EB-AEDC-2C932A6B6470 Q37087480-541102AF-C755-4A4D-AF6E-AA0C79F3DB2F Q37124032-3F0F1D77-DF1D-49DF-828E-C9B5B06B2ABC Q37260627-416196C1-CA2F-4464-806B-4971E4E144EA Q37305032-3F498D6B-58E1-43D1-80A4-42FBDB841858 Q37544607-8F309292-2821-4785-AF0E-72367FC07450 Q37550108-FE2F46BF-9E46-4A8A-B7F4-86A725E08922 Q37673542-D590588A-CC03-414F-918A-A717631ADF55 Q37680481-536FA066-5BD6-4ED0-9120-403DB0EC59E7 Q37721403-DD4FA2AF-4FAA-466F-9F6D-A7BFB6A50F47 Q37743525-0BEB6BD4-84F3-46C2-8C1E-5486AE340A14

P2860

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

http://www.wikidata.org/entity/Q24655506

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

OPT-80 eliminates Clostridium ...... ment of C. difficile infection

@ast

OPT-80 eliminates Clostridium ...... ment of C. difficile infection

@en

OPT-80 eliminates Clostridium ...... ment of C. difficile infection

@nl

type

label

OPT-80 eliminates Clostridium ...... ment of C. difficile infection

@ast

OPT-80 eliminates Clostridium ...... ment of C. difficile infection

@en

OPT-80 eliminates Clostridium ...... ment of C. difficile infection

@nl

prefLabel

OPT-80 eliminates Clostridium ...... ment of C. difficile infection

@ast

OPT-80 eliminates Clostridium ...... ment of C. difficile infection

@en

OPT-80 eliminates Clostridium ...... ment of C. difficile infection

@nl

P1433

Q24655506-377EDDE6-4C6D-4856-A715-B3053A1C1D8D

P1476

Q24655506-CE727B46-49B9-4E18-8B9B-35A5E085C453

P2093

Q24655506-4DEC9A3F-6922-431C-97DF-3AA5BDE69F25

Q24655506-5638CEA3-93CB-40A9-BF7F-2C1AEC55ED21

Q24655506-7E89664B-FD4B-42F5-B697-FB6DC40B0509

Q24655506-86A35383-1078-44D3-B737-F014A443046C

Q24655506-D1D272D6-01F9-47CC-A6D9-D0EEA7E03EFD

P2860

Q24655506-0C79B94B-2964-48E0-A619-660C31966677

Q24655506-39FD8E5D-B37B-467F-97C3-3E809EA6EAA2

Q24655506-55A75D30-DBE8-4AFE-935A-00B52F18195E

Q24655506-56B3CDC2-61BC-4EA7-9411-2781E752985E

Q24655506-7315F382-6883-42F9-A31E-281980A32C09

Q24655506-D653E3D6-8A0C-4E91-8DCD-AE4A03EB8DBD

Q24655506-E040F3B2-A07F-403E-BCD1-C420C2785E47

Q24655506-E76ACB2B-53B1-4DB2-9BA9-34252342DA9F

P304

Q24655506-57DC717A-0FC8-4DBA-8C51-0F9271DB0779

P31

Q24655506-971A4886-338C-436F-8A08-E5A0DB9488E5

P3181

Q24655506-DA809169-81EA-445C-9F2A-B5A9A7DFD580

P356

Q24655506-F8169B12-5979-40D0-A843-5BD718AD0F01

P407

Q24655506-723355C8-D0CD-4793-95EE-76F2B67D601D

P433

Q24655506-9CCEA595-CFAC-42D6-AE08-4AC9EDE4AF59

P478

Q24655506-4E342506-6B85-4AEC-99D8-6CC6D90F27E0

P577

Q24655506-5A4568FD-2D70-4861-B054-0327357E843B

P698

Q24655506-7D231EB4-858C-4EE0-B4E1-111715B80F46

P921

Q24655506-5999CE4D-218F-45E8-9827-295F0F70A413

P932

Q24655506-270DA7CF-E2A0-4708-8E5E-12EC6DB78A3C

P3181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

OPT-80 eliminates Clostridium ...... ment of C. difficile infection

@en

P2093

Brendan Byrne

http://www.w3.org/2001/XMLSchema#string

Judy Emery

http://www.w3.org/2001/XMLSchema#string

Manuel Mah

http://www.w3.org/2001/XMLSchema#string

Thomas J Louie

http://www.w3.org/2001/XMLSchema#string

Walter Krulicki

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

Colonic microbiota signatures across five northern European countries.

In vitro activity of OPT-80 against Clostridium difficile.

Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy.

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.

P304

261-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2254235

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.01443-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18955523

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

P932

2612159

http://www.w3.org/2001/XMLSchema#string